In Brief: Aastrom Biosciences/Rhone-Poulenc Rorer
This article was originally published in The Gray Sheet
Aastrom Biosciences/Rhone-Poulenc Rorer: Enter collaborative agreement to develop the automated Aastrom cell production system (CPS) for use in lymphoid cell and gene therapies in patients suffering from immune disorders. Under terms of the agreement, Ann Arbor, Michigan-based Aastrom grants Rhone exclusive rights to use and sell the CPS device for the "production, expansion or genetic manipulation of lymphoid cells," including T-cells and B-cells, while Aastrom retains all rights to other applications of the system. In return, Rhone will contribute more than $25 mil. to "R&D support, milestone fees, and purchases of Aastrom equity," subject to certain conditions...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.